Combined biopsy data can be integrated with additional omics layers through several new approaches. A multimodal data fusion allows the integration of radiomics, proteomics, transcriptomics, and metabolomics with the genomic data from dual biopsies, providing holistic tumor characterization. All intelligence-driven frameworks can integrate these different data types, capturing the longitudinal evolution of biomarkers and complex tumor biology...
Combined biopsy data can be integrated with additional omics layers through several new approaches. A multimodal data fusion allows the integration of radiomics, proteomics, transcriptomics, and metabolomics with the genomic data from dual biopsies, providing holistic tumor characterization. All intelligence-driven frameworks can integrate these different data types, capturing the longitudinal evolution of biomarkers and complex tumor biology. Future evolutions may include the integration of immunomics and spatial transcriptomics with conventional multiomics data to comprehensively characterize the tumor microenvironment. Advanced machine learning techniques excel at extracting meaningful patterns across integrated omics data sets while preserving biologically relevant signals. This allows for more precise therapeutic targeting based on comprehensive molecular profiles. Liquid biopsy combined with artificial intelligence algorithms could identify cancer-specific molecular signatures with remarkable sensitivity and enable dynamic monitoring of tumor evolution and therapeutic response in real-time.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
